Ra’anana, Israel , Dec. 04, 2025 (GLOBE NEWSWIRE) -- In an era where airborne threats like allergens and viruses disrupt daily life for millions, a small biotech innovator in Israel is quietly reshaping approaches to respiratory defense. Polyrizon Ltd. (Nasdaq: PLRZ), a development-stage biotechnology company, aims to transform a bold lab-born vision into a scalable reality. With the recent announcement of a pivotal manufacturing milestone, Polyrizon is no longer just a promising startup-it is advancing its efforts to develop non-pharmacological solutions that could shield global populations from seasonal woes and beyond.
From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection
